Get started
Author

Xianping Lu

Observed names: X Lu, X P Lu, X. Lu, X. P. Lu, X.-P. Lu, X.P. Lu, Xian-Ping Lu, Xian‐Ping Lu, Xiunan Lu, Xue-Qiang Lu, Xue-an Lu
Observed institutions: Sun Yat-sen University, Northeast Agricultural University, Sanford Burnham Prebys Medical Discovery Institute, Chinese Academy of Sciences, Chinese Academy of Medical Sciences & Peking Union Medical College, Sun Yat-sen Memorial Hospital, Huaian First People’s Hospital, Jinshan Hospital of Fudan University, Chung Shan Medical University Hospital, Institute of Process Engineering, Shenzhen Chipscreen Biosciences Co., Research Institute of Tsinghua University in Shenzhen, The People's Hospital of Chuxiong Yi Autonomous Prefecture, Tsinghua University
ORCID: 0000-0003-3933-0931
Observed ORCID: 0000-0003-3933-0931
OpenAlex ID: A5085142395
Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma
2015 · Y. Shi, M. Dong, et al. · Annals of Oncology · 387
Chidamide (CS055/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity
2011 · Zhi-Qiang Ning, Zhi-Bin Li, et al. · Cancer Chemotherapy and Pharmacology · 305
Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial
2019 · Zefei Jiang, Wei Li, et al. · The Lancet Oncology · 271
Advances in targeting histone deacetylase for treatment of solid tumors
2024 · Mu-Qi Shi, Ying Xu, et al. · Journal of Hematology & Oncology · 181
Development of chidamide for peripheral T-cell lymphoma, the first orphan drug approved in China
2016 · Xianping Lu, Zhiqiang Ning, et al. · Intractable & Rare Diseases Research · 175
PDF
Naringenin and hesperetin, two flavonoids derived from Citrus aurantium up‐regulate transcription of adiponectin
2008 · Li Liu, Song Shan, et al. · Phytotherapy Research · 127
Phase I study of chidamide (CS055/HBI-8000), a new histone deacetylase inhibitor, in patients with advanced solid tumors and lymphomas
2012 · Mei Dong, Zhi-Qiang Ning, et al. · Cancer Chemotherapy and Pharmacology · 122
Therapeutic potential of tucidinostat, a subtype-selective HDAC inhibitor, in cancer treatment
2022 · Yichen Sun, Jing Han Hong, et al. · Frontiers in Pharmacology · 94
PDF
Novel retinoid-related molecules as apoptosis inducers and effectve inhibitors of human lung cancer cells in vivo
1997 · Xian-Ping Lu, Andrea Fanjul, et al. · Nature Medicine · 87
Non-toxic dose chidamide synergistically enhances platinum-induced DNA damage responses and apoptosis in Non-Small-Cell lung cancer cells
2014 · You Zhou, De-Si Pan, et al. · Biomedicine & Pharmacotherapy · 75
The PPARα/γ dual agonist chiglitazar improves insulin resistance and dyslipidemia in MSG obese rats
2006 · Ping‐Ping Li, Song Shan, et al. · British Journal of Pharmacology · 72
PDF
Efficacy and safety of chiglitazar, a novel peroxisome proliferator-activated receptor pan-agonist, in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, phase 3 trial (CMAP)
2021 · Linong Ji, Weihong Song, et al. · 中国科学通报：英文版 · 68
PDF
Discovery of an orally active subtype-selective HDAC inhibitor, chidamide, as an epigenetic modulator for cancer treatment
2014 · De-Si Pan, Qian-Jiao Yang, et al. · MedChemComm · 62
Nuclear Retinoid Receptors and Their Mechanism of Action
1994 · Magnus Pfahl, Rainer Apfel, et al. · Vitamins and hormones · 61
Progastrin1–80stimulates growth of intestinal epithelial cells in vitro via high-affinity binding sites
2003 · P. Singh, X. Lu, et al. · American Journal of Physiology-Gastrointestinal and Liver Physiology · 60
In VitroandIn VivoCharacterizations of Chiglitazar, a Newly Identified PPAR Pan-Agonist
2012 · B. K. He, Z. Q. Ning, et al. · PPAR Research · 56
PDF
Chiglitazar monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomized, double-blind, phase 3 trial (CMAS)
2021 · Weiping Jia, Jianhua Ma, et al. · 中国科学通报：英文版 · 50
PDF
CS 2164, a novel multi‐target inhibitor against tumor angiogenesis, mitosis and chronic inflammation with anti‐tumor potency
2016 · You Zhou, Song Shan, et al. · Cancer Science · 49
PDF
Down-regulation of prostate specific antigen in LNCaP cells by flavonoids from the pollen of Brassica napus L.
2006 · H.Y. Han, S. Shan, et al. · Phytomedicine · 48
DNA Bending by Retinoid X Receptor-Containing Retinoid and Thyroid Hormone Receptor Complexes
1993 · X P Lu, N L Eberhardt, et al. · Molecular and Cellular Biology · 46
Quantitative Structure-Activity Relationship Study of Histone Deacetylase Inhibitors
2004 · Aihua Xie, Chenzhong Liao, et al. · Anti-Cancer Agents in Medicinal Chemistry · 45
Chiglitazar Preferentially Regulates Gene Expression via Configuration-Restricted Binding and Phosphorylation Inhibition of PPARγ
2017 · De-Si Pan, Wei Wang, et al. · PPAR Research · 44
PDF
Resveratrol alleviates Mono-2-ethylhexyl phthalate-induced mitophagy, ferroptosis, and immunological dysfunction in grass carp hepatocytes by regulating the Nrf2 pathway
2024 · Xiaodan Wang, Meichen Gao, et al. · Journal of Environmental Management · 43
A selective retinoid with high activity against an androgen-resistant prostate cancer cell type
1999 · Xian-Ping Lu, Andrea Fanjul, et al. · International Journal of Cancer · 43
PDF
Analysis of blood methylation quantitative trait loci in East Asians reveals ancestry-specific impacts on complex traits
2024 · Qianqian Peng, Xinxuan Liu, et al. · Nature Genetics · 42
PDF
Works count: 66
Citation count: 2,882
H-index: 26
I10-index: 38
Year
Topic
Type